May 11, 2015
MusclePharm Reports 2015 First Quarter Financial Results
Net Revenue of $41.3 million
Record Sales Backlog of $17.1 million
$3.8 million Cash Flow Positive with $4.8 million in Cash
Reaffirms Guidance of $210-$220 million Net Revenue for 2015
DENVER, CO -- (Marketwired) -- 05/11/15 -- MusclePharm Corporation(OTCQB: MSLP) (“MusclePharm” or the “Company”), a scientifically driven, performance-lifestyle sports nutrition company, today announced financial results for the first quarter ended March 31, 2015.
Operating and Financial Highlights for First Quarter 2015
| · | Net revenue of $41.3 million - 26% growth sequentially quarter-over-quarter; |
| · | $3.8 million cash flow positive for Q1 with $4.8 million in cash; |
| · | Cash flow increased $5.9 million - a year-over-year increase of 282%; |
| · | $17.1 million sales backlog, an increase of $12 million quarter-over-quarter; |
| · | Gross margin increased to 34.8%, up 320 basis points versus 2014 full year results and 1170 basis points sequentially of 51%. |
“We were very pleased with the fundamentals of our business in the first quarter and the positive momentum we have built in continued revenue contributions, positive cash flow and sustainable margins,” said Brad Pyatt, MusclePharm's chairman and chief executive officer. “While our year-over-year revenue was down slightly, due largely to the timing of our key Arnold Classic sales event, we closed the quarter with $17.1 million in sales backlog orders and we are on track for strong revenue growth for the remainder of the year driven by the continued strengthening of our core products, new product releases, expanding our distribution network and entering into new retail outlets. At the same time, we are actively managing our cash position, with strong increases in cash flow this quarter, and managing our operating expenses, with initiatives in place to keep costs in line for the remainder of the year. We believe we are well positioned for continued top line growth as we approach our goal of profitability and long-term shareholder value creation.”
Recent Highlights
| · | Grew distribution network substantially with 45,000 retailers, up from 35,000 at the end of 2014, and 120 international countries supported, up from 110 at the end of 2014. |
| · | Launched the MusclePharm Black Label, designed for elite, high-performing athletes exclusively at GNC stores and GNC.com. |
| · | Entered into the energy drink category, currently a $9 billion market in the US and $27 billion globally, with five SKUs launched this quarter. |
| · | Executed a manufacturing agreement with Capstone Nutrition with an option to complete an acquisition within the next 18 months to enhance vertical integration strategy. |
| · | Improved corporate governance best practices, announcing the intention to separate the role of Chairman of the Board, with Brad Pyatt remaining the CEO, and increase the number of directors on the Board to seven, with five independent directors. |
Financial Results for First Quarter 2015
Net revenue was $41.3 million, an increase of 26% sequentially quarter-over-quarter. The Company also closed the quarter with a sales backlog of $17.1 million compared to $5.1 million at the end of the year 2014 and $9.1 million at the end of the first quarter 2014. This growth in backlog was largely due to the timing of a key company sales event, the Arnold Classic, which was held later in the quarter, resulting in order fulfillment and revenue recognition in the second quarter of 2015. Net revenues also reflected slower than expected international sales due to currency fluctuations and the strength of the U.S. dollar. The Company has taken significant steps to globalize our supply chain to address this issue.
Cash flow increased $5.9 million, or 282%, to a positive $3.8 million from negative $2.1 million in the year prior. Even with a lower top line performance, the Company increased its end of quarter cash position by nearly $4 million.
Gross margin was 34.8%, up 320 basis points over the 2014 full year gross margin.
Adjusted EBITDA, a non-GAAP measure was ($1.6) million, which eliminates depreciation, amortization, interest, taxes, stock-based compensation, and other expenses.
Reaffirmed 2015 Full-Year Guidance
| · | Net revenue is expected to be in the range of $210 to $220 million. |
| · | Sustainable gross margin is expected to be in the range of 31 to 33 percent. |
2015 First Quarter Conference Call Information
When:Tuesday, May 12, 2015
Time:8:00 a.m. Eastern Time
Phone:1-877-407-9126 (domestic)
1-201-493-6751 (international)
A live webcast will be available online on MusclePharm's website at
http://ir.musclepharmcorp.com, where it will be archived for one year.
An audio replay of the conference call will be available through midnight May 19 by dialing 877-660-6853 from the U.S. or Canada, or 201-612-7415 from international locations, passcode 13581597.
About MusclePharm
MusclePharm® is a scientifically-driven, performance lifestyle company that currently develops, manufactures, markets and distributes branded nutritional supplements. The company offers a complete range of powders, capsules, tablets and gels. Its portfolio of recognized brands, including MusclePharm® Hybrid and Core Series, Arnold Schwarzenegger Series™ and FitMiss™, are marketed and sold in more than 120 countries and available in over 45,000 retail outlets globally. These clinically-proven and scientific nutritional supplements are developed through a six-stage research process utilizing the expertise of leading nutritional scientists, doctors and universities. MusclePharm is the innovator of the sports nutrition industry. For more information, visit http://www.musclepharm.com. Follow MusclePharm Corporation on Facebook, Twitter, and Instagram.
To sign up to receive MusclePharm news via email, please visit
http://ir.musclepharmcorp.com/email-alerts
Non-GAAP Financial Measures
In addition to disclosing financial results calculated in accordance with U.S. Generally Accepted Accounting Principles (GAAP), the earnings release contains non-GAAP financial measures adjusted for income taxes, depreciation and amortization of property and equipment, amortization of intangible assets, provision for doubtful accounts, amortization of prepaid stock compensation, amortization of prepaid sponsorship fees, stock based compensation, and issuance of common stock warrants. Management believes that the non-GAAP measures used in this release provide investors with important perspectives into the Company's ongoing business performance. The non-GAAP financial measures disclosed by the Company should not be considered a substitute for, or superior to, financial measures calculated in accordance with GAAP, and the financial results calculated in accordance with GAAP and reconciliations to those financial statements should be carefully evaluated. The non-GAAP financial measures used by the Company may be calculated differently from, and therefore may not be comparable to, similarly titled measures used by other companies. All financial data is presented on a GAAP basis except where the Company indicates its presentation is on a non-GAAP basis. Set forth below are reconciliations of non-GAAP net income (loss) to the Company's reported GAAP net income (loss).
Forward-Looking Statements
This release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities and Exchange Act of 1934, as amended. Statements that are not a description of historical facts constitute forward-looking statements and may often, but not always, be identified by the use of such words as "expects", "anticipates", "intends", "estimates", "plans", "potential", "possible", "probable", "believes", "seeks", "may", "will", "should", "could" or the negative of such terms or other similar expressions. Actual results may differ materially from those set forth in this release due to the risks and uncertainties inherent in the Company's business. More detailed information about the Company and the risk factors that may affect the realization of forward-looking statements is set forth in the Company's Annual Report on Form 10-K for the fiscal year ended December 31, 2014, the Company's Quarter Reports on Form 10-Q and other filings submitted by the Company to the SEC, copies of which may be obtained from the SEC's website at www.sec.gov. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. All forward-looking statements are qualified in their entirety by this cautionary statement and the Company undertakes no obligation to revise or update this release to reflect events or circumstances after the date hereof.
| MusclePharm Corporation | |||||
| Consolidated Balance Sheets | |||||
| In thousands |
| March 31, | December 31, | |||||||
| 2015 | 2014 | |||||||
| (unaudited) | ||||||||
| ASSETS | ||||||||
| Current assets: | ||||||||
| Cash | $ | 4,784 | $ | 1,020 | ||||
| Accounts receivable, net | 18,959 | 16,644 | ||||||
| Inventory | 13,872 | 21,069 | ||||||
| Prepaid giveaways | 1,474 | 1,228 | ||||||
| Prepaid stock compensation, current | 4,236 | 4,476 | ||||||
| Prepaid sponsorship and endorsement fees | 397 | 238 | ||||||
| Prepaid expenses and other current assets | 2,044 | 1,742 | ||||||
| Total current assets | 45,766 | 46,417 | ||||||
| Property and equipment, net | 7,470 | 7,805 | ||||||
| Intangible assets, net | 9,195 | 7,074 | ||||||
| Prepaid stock compensation, long-term | 5,282 | 4,952 | ||||||
| Other assets | 188 | 108 | ||||||
| TOTAL ASSETS | $ | 67,901 | $ | 66,356 | ||||
| LIABILITIES AND STOCKHOLDERS' EQUITY | ||||||||
| Current liabilities: | ||||||||
| Accounts payable | 28,826 | 27,761 | ||||||
| Accrued liabilities | 6,050 | 7,023 | ||||||
| Line of credit | 8,000 | 8,000 | ||||||
| Term loan, current portion | 1,271 | - | ||||||
| Other debt obligations | 46 | 46 | ||||||
| Total current liabilities | 44,193 | 42,830 | ||||||
| Term loan, non-current portion | 2,625 | - | ||||||
| Other long-term liabilities | 114 | 146 | ||||||
| TOTAL LIABILITIES | 46,932 | 42,976 | ||||||
| Commitments and contingencies | ||||||||
| Stockholders' equity: | ||||||||
| Common stock | 14 | 14 | ||||||
| Additional paid-in capital | 134,278 | 129,130 | ||||||
| Treasury stock | (10,039 | ) | (10,039 | ) | ||||
| Accumulated other comprehensive loss | (146 | ) | (66 | ) | ||||
| Accumulated deficit | (103,138 | ) | (95,659 | ) | ||||
| Total stockholders' equity | 20,969 | 23,380 | ||||||
| TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY | $ | 67,901 | $ | 66,356 | ||||
| MusclePharm Corporation | |||||
| Consolidated Statement of Operations | |||||
| In thousands, except per share amounts |
| Three months ended | ||||||||
| 3/31/2015 | 3/31/2014 | |||||||
| (unaudited) | (unaudited) | |||||||
| Revenue, net | $ | 41,322 | $ | 50,209 | ||||
| Cost of revenue | 26,938 | 32,336 | ||||||
| Gross profit | 14,384 | 17,873 | ||||||
| Operating expenses | ||||||||
| Advertising and promotion | 7,225 | 6,328 | ||||||
| Salaries and benefits | 7,061 | 5,367 | ||||||
| Selling, general and administrative | 4,962 | 1,872 | ||||||
| Research and development | 965 | 1,097 | ||||||
| Professional fees | 1,455 | 785 | ||||||
| Total operating expenses | 21,668 | 15,449 | ||||||
| (Loss) income from operations | (7,284 | ) | 2,424 | |||||
| Other (expense) income, net | (183 | ) | 344 | |||||
| (Loss) income before provision for income taxes | (7,467 | ) | 2,768 | |||||
| Provision for income taxes | 12 | 32 | ||||||
| Net (loss) income | $ | (7,479 | ) | $ | 2,736 | |||
| Net (loss) income per share, basic | $ | (0.56 | ) | $ | 0.27 | |||
| Net (loss) income per share, diluted | $ | (0.56 | ) | $ | 0.23 | |||
| MusclePharm Corporation | ||||
| Reconciliation to Non-GAAP Income (Loss) to GAAP Income | ||||
| In thousands |
| Three months ended | ||||||||
| 3/31/2015 | 3/31/2014 | |||||||
| (unaudited) | (unaudited) | |||||||
| Net (loss) income | $ | (7,479 | ) | $ | 2,736 | |||
| Non-GAAP adjustments: | ||||||||
| Provision for income taxes | 12 | 32 | ||||||
| Depreciation and amortization of property and equipment | 382 | 314 | ||||||
| Amortization of intangible assets | 225 | 285 | ||||||
| Provision for doubtful accounts | 30 | 76 | ||||||
| Amortization of prepaid stock compensation | 1,109 | 795 | ||||||
| Amortization of prepaid sponsorship fees | 1,431 | 1,658 | ||||||
| Stock-based compensation | 2,522 | 2,376 | ||||||
| Issuance of common stock warrants to third parties for services | 33 | - | ||||||
| Other expense (income), net | 183 | (344 | ) | |||||
| Adjusted EBITDA | $ | (1,552 | ) | $ | 7,928 | |||
Media:
Becky Warren
(916) 607-0129
bwarren@mercuryllc.com
Investors:
Allyson Vento and Dana Gorman
Abernathy MacGregor Group
(212) 371-5999
AMV@abmac.com / DTG@abmac.com